Swedish and international institutional investors.
NeuroVive Pharmaceutical (publ) is a leading mitochondrial medicine company, engaged in the development of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. The addressable medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s share is listed on Nasdaq, Stockholm.
Directed issue to a number of Swedish and international institutional investors of SEK 65 million to fund the commercialization and further development of NeuroVive’s product portfolio.
HDR Partners acted as financial advisor and outlined equity story and investor presentations, identified potential investors and led valuation negotiations.